Symbol="ALGS"
AssetType="Common Stock"
Name="Aligos TherapeuticsÂ Inc"
Description="Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California."
CIK="1799448"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="38839300"
EBITDA="-83857000"
PERatio="None"
PEGRatio="None"
BookValue="1.974"
DividendPerShare="0"
DividendYield="0"
EPS="-1.89"
RevenuePerShareTTM="0.329"
ProfitMargin="0"
OperatingMarginTTM="-6.11"
ReturnOnAssetsTTM="-0.323"
ReturnOnEquityTTM="-0.702"
RevenueTTM="14059000"
GrossProfitTTM="-71170000"
DilutedEPSTTM="-1.89"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.059"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.788"
PriceToBookRatio="0.351"
EVToRevenue="69.48"
EVToEBITDA="0.793"
Beta="2.233"
num_52WeekHigh="2.41"
num_52WeekLow="0.84"
num_50DayMovingAverage="1.046"
num_200DayMovingAverage="1.184"
SharesOutstanding="39847800"
DividendDate="None"
ExDividendDate="None"
symbol="ALGS"
open="0.90"
high="0.92"
low="0.87"
price="0.88"
volume="66889.00"
latest_trading_day="2023-07-27"
previous_close="0.90"
change="-0.03"
change_percent="-3.2615%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="64"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="36"
Volume_recent_avg="177402"
Change_recent_avg="-0.01"
Delta_recent_avg="0.1"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-1.14"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="36"
Aroon_momentum_negative="64"
image_negative_thumbnail_id_1="1156"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0190.jpeg"
image_negative_thumbnail_id_2="1108"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0141.jpeg"
image_neutral_thumbnail_id_1="532"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0067.jpeg"
image_neutral_thumbnail_id_2="552"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0047.jpeg"
image_positive_thumbnail_id_1="986"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0148.jpeg"
image_positive_thumbnail_id_2="1000"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0162.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
